Clinical Trials Logo

Filter by:
NCT ID: NCT05043142 Completed - Covid19 Clinical Trials

Epidemiological Study of the COVID-2019 in Participating Organizations.

Start date: March 16, 2021
Phase:
Study type: Observational

Exhaustive, cross-sectional, non-interventional, multicenter retrospective epidemiological study, case study aimed to determine the relationship between the systematic use of prophylactics to prevent SARS, including COVID-2019, and the risks of incidence and serious complications of COVID-2019 among staff of participating organizations.

NCT ID: NCT05042024 Completed - Periodontitis Clinical Trials

Supplementation With L-ornithine But Not L-arginine Increases Density of CD68+ and CD163+ Macrophages in Periodontitis

Start date: October 20, 2017
Phase: Phase 3
Study type: Interventional

The aim of the study was to investigate whether oral administration of L-arginine or L-ornithine could modulate local representation density and ratio of macrophages in periodontitis-affected gingiva by using immunohistochemical detection of CD68+ and CD163+ macrophages in biopsies of the gingiva. The null hypothesis tested was that L-arginine and L-ornithine have no influences on CD68+ and CD163+ macrophages densities when supplementing the treatment of periodontitis. Materials and methods. 75 individuals with a diagnosis of generalized periodontitis at stages II-III and grade B (38 women and 37 men, 51% and 49%, respectively) were included in the study. Periodontitis was diagnosed by using the criteria of the Classification of Periodontal and Peri-Implant Diseases and Conditions 2017. 25 patients received scaling and root planing only; 25 patients additionally received L-arginine, and 25 - L-ornithine, according to instructions available in Ukraine. For the immunohistochemical study of paraffin-embedded sections, the gingival biopsy was taken from 5 selected patients per group before treatment and after 1 month. CD68+ (cluster of differentiation 68 positive) and CD163+ cells served as a morphological equivalent of M1, M2 macrophages subpopulations, and their densities were calculated per 10000 μm2. Statistical analysis was performed by adequate power methods.

NCT ID: NCT05028387 Not yet recruiting - Pregnancy Clinical Trials

Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.

Start date: September 2021
Phase:
Study type: Observational

The goal of this study is to pilot and evaluate a telemedicine medical abortion service delivery that allows remote communication between the woman and provider and limits medically unnecessary in-person visits to health or diagnostic centers.

NCT ID: NCT05014321 Active, not recruiting - Lentigo Solar Clinical Trials

Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots PROOF OF CONCEPT

CRYO-EC4
Start date: May 14, 2021
Phase: N/A
Study type: Interventional

CRYO (N° 21D588A0001) study aims to evaluate the tolerance and adjust the mode of administration of a cyto-selective difluoroethane-based cryotherapy in the treatment of brown spots. The study is a proof of concept on a small panel of subjects and has been designed to be interventional, monocentric, randomized and double blind. The study will include three device prototypes and a CE marked device (trademark URGO CRYOBEAUTY MAINS-BRAS-JAMBES) used as reference.

NCT ID: NCT05012787 Not yet recruiting - COVID-19 Clinical Trials

A Study of Safety and Immunogenicity of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adults With Chronic Immune-Mediated Diseases

Start date: September 13, 2021
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the safety and immunogenicity of the investigational CpG 1018/Alum-adjuvanted recombinant SARS-CoV-2 trimeric spike (S)-protein subunit vaccine (SCB-2019) in adult participants with stable chronic inflammatory immune-mediated diseases (IMDs), compared to control vaccine.

NCT ID: NCT04990440 Recruiting - Dermatitis, Atopic Clinical Trials

A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

Start date: September 15, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of Bermekimab, compared with placebo, in participants with moderate-to-severe atopic dermatitis (AD).

NCT ID: NCT04985812 Not yet recruiting - Clinical trials for Rheumatoid Arthritis

A Study of JNJ-67484703 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Start date: August 25, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate safety and tolerability of JNJ-67484703 administrations in participants with active rheumatoid arthritis (RA) despite receiving methotrexate (MTX) therapy.

NCT ID: NCT04978337 Not yet recruiting - Clinical trials for Respiratory Syncytial Virus

A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection

PRIMROSE
Start date: October 4, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of rilematovir compared to placebo with respect to the time to resolution of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) symptoms.

NCT ID: NCT04976244 Recruiting - Pathologic Myopia Clinical Trials

Brolucizumab for CNV Associated With Pathologic Myopia

COASTUAbaCNV
Start date: April 1, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the effectiveness of antiangiogenic therapy to choroidal neovascularization secondary to pathologic myopia.

NCT ID: NCT04975308 Not yet recruiting - Breast Neoplasms Clinical Trials

Study of LY3484356 Versus Hormone Therapy, in Participants With Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer

EMBER-3
Start date: September 20, 2021
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to measure how well LY3484356 works compared to hormone therapy in participants with breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have breast cancer that is advanced or has spread to another part of the body. Study participation could last up to 5 years.